June 8, 2020 -- Eli Lilly and its partner Junshi Biosciences of Shanghai, China, have begun a phase I clinical trial for Eli Lilly's second COVID-19 antibody therapy.
JS016 is a recombinant, fully human monoclonal antibody that specifically binds to the SARS-CoV-2 spike protein receptor-binding domain. Lilly and Junshi Biosciences are developing it together in China; Lilly has exclusive rights to develop the therapy for the rest of the world and plans to begin a trial with patients in the U.S. soon, it said. Both companies will assess the safety, pharmacokinetics, and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19, according to Lilly.
JS016 is Lilly's second antibody treatment for COVID-19 to undergo clinical trials. The first, LY-CoV555, is in a phase I trial and is being tested in patients hospitalized for the disease.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
